Hyaluronan Inhibitors
10 drugsAbout Hyaluronan
Hyaluronan, or hyaluronic acid (HA), is a glycosaminoglycan distributed throughout the body. It plays roles in tissue hydration, cell migration, and inflammation.
Hyaluronan's involvement in various biological processes makes it a target for drug development. Currently, there is no genetic evidence data available linking hyaluronan to specific diseases.
Hyaluronan is targeted by 11 FDA-approved drugs, including OPDIVO QVANTIG, RITUXAN HYCELA and VYVGART HYTRULO. These drugs are primarily biologics (73%) and antibodies (27%), with applications mainly in oncology.
Top Hyaluronan Drugs
The competitive landscape includes 5 companies with approved drugs, led by Roche and Bristol-Myers Squibb.
Relatively low number of players suggests moderate barriers to entry, but high competition among incumbents.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| KEYTRUDA QLEX | Merck | 2025 | 2 |
| VYVGART HYTRULO | ARGENX BV | 2023 | 2 |
| DARZALEX FASPRO | Johnson & Johnson | 2020 | 1 |
| RYBREVANT FASPRO | Johnson & Johnson | 2025 | 1 |
| HERCEPTIN HYLECTA | Roche | 2019 | 1 |
| OCREVUS ZUNOVO | Roche | 2024 | 1 |
| TECENTRIQ HYBREZA | Roche | 2024 | 1 |
Hyaluronan Drug Modality Landscape
Modalities
Routes of Administration
Hyaluronan requires biologic approaches (biologic (other)), likely due to its structure or location.
Small molecule approaches may represent a whitespace opportunity to differentiate from existing biologics.
📈 Modality Evolution
Antibodies pioneered Hyaluronan targeting (2017), with enzymes entering more recently (2023).
Hyaluronan Clinical Trials 6,120 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Hyaluronan. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2149 | 832 | 505 | 792 | 62% |
| Phase 2 | 2935 | 1000 | 576 | 1341 | 63% |
| Phase 3 | 926 | 351 | 111 | 464 | 76% |
| Phase 4 | 110 | 48 | 13 | 49 | 79% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved Hyaluronan drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Hyaluronan. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Hyaluronan Drug Approval Timeline (2017 - 2025)
The first drug was approved in 2017 (RITUXAN HYCELA), with the most recent in 2026 (RYBREVANT FASPROI).
Recent approvals suggest continued interest, but approaching saturation may increase competition.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 10 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 10-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1,459 (562 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Hyaluronan. A trial counts if an approved drug acting on Hyaluronan is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.